A CLOSE PARALLELISM EXISTS between inhibition of agonist-induced inositol 1,4,5-trisphosphate (IP 3 )-dependent Ca 2ϩ release by cAMP-and cGMP-dependent protein kinases (PKA and PKG) and inhibition of muscle contraction (i.e., relaxation). PKA and/or PKG can regulate Ca 2ϩ mobilization by acting on various molecular targets, including IP 3 generation (19, 33, 34) and sarcoplasmic IP 3 receptors (IP 3 R)/Ca 2ϩ channels (9, 10) , which determine Ca 2ϩ release, plasmalemmal and sarcoplasmic Ca 2ϩ /ATPase pumps, which determine Ca 2ϩ uptake into intracellular stores or efflux from the cell (2, 14) , and plasmalemmal Ca 2ϩ and K ϩ channels, which regulate membrane polarity and Ca 2ϩ influx via voltage-dependent Ca 2ϩ channels (25) . Activation of PKG or PKA inhibits agonist-induced Ca 2ϩ release in intact visceral smooth muscle cells (17, 19) and IP 3 induced Ca 2ϩ release in permeabilized visceral smooth muscle cells (17) . Inhibition of agonist-induced Ca 2ϩ release could result from inhibition of IP 3 formation, whereas inhibition of IP 3 -induced Ca 2ϩ release in permeabilized muscle probably reflects phosphorylation of the IP 3 R by either kinase. Studies in vascular smooth muscle suggest that both kinases are capable of phosphorylating IP 3 R in vitro, whereas only PKG phosphorylates IP 3 R in vivo (9, 10) . Permeabilization may allow access of PKA to the IP 3 R that is normally denied to this kinase in intact smooth muscle cells.
Two PKG isoforms, PKG-I␣ and PKG-I␤, have been implicated in IP 3 R-I phosphorylation. Although both isoforms are frequently colocalized, PKG-1␣ appears to be more widely distributed in human, bovine, rabbit, and murine tissues (5, 7, 11, 29, 35) . PKG-I␣ is 10-fold more sensitive to activation by cGMP and is more susceptible to cross-activation by cAMP (12, 29) . Both kinases recognize in vivo substrates by interaction with their distinctive NH 2 -terminal leucine-zipper amino acid sequences (1, 32) . A 125-kDa protein, IP 3 -R-associated cG-kinase substrate (IRAG), has been recently identified that binds to both the IP 3 R and the distinctive NH 2 -terminal sequence of PKG-1␤ (1, 28) . In cells expressing IP 3 R-I, IRAG, and PKG-I␤, all three proteins are coimmunoprecipitated by antibodies to each. Reconstitution studies in COS-7 cells suggest that phosphorylation of IRAG at Ser 696 is a prerequisite for IP 3 R phosphorylation and inhibition of IP 3 -dependent Ca 2ϩ release by PKG-I␤ (28) . However, recent studies in native mouse aortic smooth muscle cells that normally express IRAG and both PKG-I isoforms have raised doubts regarding the functional role of PKG-I␤ (3). Transfection of PKG-I␣ into smooth muscle cells derived from PKG-I␣-and -I␤-deficient mice restored the ability of PKG activators [nitric oxide (NO) donors and 8-bromo-cGMP] to inhibit agonistinduced Ca 2ϩ transients, whereas transfection of PKG-I␤ had no effect (3) .
In the present study, we have examined the expression of IP 3 R types and PKG isoforms in freshly dispersed and cultured gastric smooth muscle cells and determined the ability of PKG and PKA to phosphorylate IP 3 Rs in vivo and inhibit IP 3 -dependent Ca 2ϩ release from isolated sarcoplasmic microsomes. The results indicate that PKG and PKA induce in vitro phosphorylation of IP 3 R-I expressed in smooth muscle cells. IP 3 R-I phosphorylation in vivo is mediated exclusively by PKG and is partly responsible for inhibition of IP 3 -dependent Ca 2ϩ release.
MATERIALS AND METHODS
Preparation of dispersed gastric smooth muscle cells. Dispersed gastric smooth muscle cells were prepared by sequential enzymatic digestion, filtration, and centrifugation as described previously (16, 17, 19, 20) . The partly digested strips were washed twice with 50 ml of enzyme-free medium, and the muscle cells were allowed to disperse spontaneously for 30 min. The cells were harvested by filtration through 500-m Nitex (Tetko, Briarcliff Manor, NY) and centrifuged twice at 350 g for 10 min. For permeabilization, dispersed smooth muscle cells were treated for 5 min with saponin (35 g/ml) and resuspended in low-Ca 2ϩ (100 nM) medium as previously described (16, 17) . In some experiments, the cells were placed in culture in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum until they attained confluence.
RT-PCR analysis of IP 3R types, PKG isoforms, and IRAG. Specific primers were designed for IP3R-I, -II, and -III based on homologous sequences in human, bovine, and rat cDNAs, for IRAG based on homologous sequences in bovine and human IRAG cDNAs, for PKG-I␣ based on the sequence of rabbit PKG-I␣ cDNA, and for PKG-I␤ based on homologous sequences in human, bovine, and mouse cDNAs. The sequences of the primers are listed in Table 1. RNA (5 g) prepared from cultured rabbit gastric smooth muscle cells was reversibly transcribed and amplified by PCR under standard conditions (2 mM MgCl 2, 200 M dNTP, and 2.5 units of Taq polymerase) in a final volume of 50 l containing 100 ng of each primer. The PCR products were separated by electrophoresis in 1.2% agarose gel in the presence of ethidium bromide, visualized by ultraviolet fluorescence, and recorded by a ChemiImager 4400 Fluorescence system. PCR products were purified by gel extraction kit and sequenced.
Western blot analysis of IP 3R. The expression of IP3Rs was determined by Western blot as described previously (18) using homogenates prepared from freshly dispersed gastric smooth muscle cells. Proteins were resolved by 7.5% SDS-PAGE and elelctrophoretically transferred to nitrocellulose membranes. The membranes were incubated for 12 h at 4°C with specific antibodies for IP 3R-I, -II, or -III and then for 1 h with secondary antibody. The bands were identified by enhanced chemiluminescence.
In vivo phosphorylation and immunoprecipitation of IP3R-I. Phosphorylation of IP3R-I was determined from the amount of 32 P incorporated after immunoprecipitation with specific IP3R-I antibody as previously described for other proteins (18) . Ten milliliters of smooth muscle cell suspension (4 ϫ 10 6 cells/ml) were incubated with [ 32 P]orthophosphate for 4 h at 31°C. Samples (1 ml) were reincubated with PKA or PKG activators for 1 min in the presence or absence of the specific PKG or PKA inhibitors. The reaction was terminated with an equal volume of lysis buffer. The cell lysates were separated from the insoluble material by centrifugation at 13,000 g for 15 min at 4°C, precleared with 40 l of protein A-sepharose, and incubated overnight with IP3R-I antibody at a final concentration of 5 g/ml. Protein A/G-sepharose was then added for 1 h, and the mixture was centrifuged for 5 min. The immunoprecipitates were washed four times with the lysis buffer and resuspended in Laemmli buffer and boiled for 15 min. The proteins were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes. [ 32 P]IP3R-I was visualized by autoradiography, and the amount of radioactivity in the bands was counted. Immunoblot analysis was performed on the membranes after autoradiography to determine comigration of IP3R-I with the corresponding radioactive bands.
In vitro phosphorylation of IP3R-I. IP3R-I immunoprecipitates were washed five times with lysis buffer and phosphorylated in the presence of exogenous PKG-I␣ holoenzyme (0.5 M) or the catalytic subunit of PKA (0.5 M). Phosphorylation with the catalytic subunit of PKA was performed in a medium containing 20 mM Tris ⅐ HCl (pH 7.4), 10 mM MgCl2, 1 mM EGTA, 10 M cAMP, 6 mM p-nitrophenylphosphate, 12 mM ␤-glycerophosphate, and 20 M sodium vanadate. Phosphorylation with the purified holoenzyme of PKG-I␣ was performed in the presence of PKI14-22 amide and 10 M cGMP instead of cAMP. Phosphorylation was initiated by the Back phosphorylation of IP 3R. A back-phosphorylation approach was also used to determine in vivo phosphorylation of IP 3R-I (10). IP3R-I immunoprecipitates derived from control smooth muscle cells and cells treated with activators of PKA or PKG were phosphorylated in vitro using [␥-
32 P]ATP in the presence of exogenous PKG-I␣ holoenzyme as described in In vitro phosphorylation of IP 3R-I. The amount of 32 P incorporated into the immunoprecipitated IP3R-I derived from control muscle cells was taken as 100%, and the amount of 32 P incorporated into the immunoprecipitated IP3R-I derived from cells treated with PKA or PKG activators was calculated as a percentage of the control value. The decrease in 32 P incorporation after treatment with PKA and PKG activators reflected endogenous phosphorylation by PKA or PKG.
Ca 2ϩ release from smooth muscle microsomes. The effect of IP3R-I phosphorylation on IP3-induced Ca 2ϩ release was measured in microsomes prepared from freshly dispersed smooth muscle cells and preloaded with 45 Ca 2ϩ as described previously (16) . One-milliliter samples (0.5 mg) of the microsomal suspension were incubated for 60 min at 31°C with 45 Ca 2ϩ (10 Ci/ml), ATP (1 mM), and ATP regenerating system when a steady state of Ca 2ϩ uptake was reached (16) . After the addition of IP3, 100-l samples were removed at 15 s and added to 25 l of quench medium consisting 0.633 M formalin and 50 mM EDTA (pH 7.0). The samples were centrifuged at 13,000 g for 5 min, and the pellets were washed twice with the same medium and extracted with 50 l of tricholoroacetic acid for measurement of 45 Ca 2ϩ . Before the addition of IP3 in some experiments, the microsomes were treated with the PKG-I␣ holoenzyme (0.5 M) in the presence of 10 M cGMP or with the catalytic subunit PKA (0.5 M) for 15 min.
Materials. [␥-32 P]ATP and [ 32 P]orthophosphate were obtained from Amersham Pharmacia Biotech (Piscataway, NJ); collagenase and soybean trypsin inhibitor were from Worthington Biochemical (Freehold, NJ); 8-(4-chlorophenylthio) guanosine 3Ј,5Ј-cyclic monophosphate (8-pCPT-cGMP) and 5,6-dichloro-1-␤-D-ribofuranosyl benzimidazole 3Ј,5-cyclic monophosphothioate, Sp-isomer (cBIMPS) were from Alexis Biochemicals (San Diego, CA); IP 3 was from Calbiochem (San Diego, CA); Western blotting and chromatography material and protein assay kit were from Bio-Rad Laboratories (Hercules, CA); antibody to IP 3R types I, II, and III were from Santa Cruz (Santa Cruz, CA). All other chemicals were obtained from Sigma (St. Louis, MO). 3 R types, PKG isoforms, and IRAG in gastric smooth muscle. PKG-I␣ and PKG-I␤ were detected by RT-PCR in primary cultures of gastric smooth muscle cells and after first passage using specific primers based on conserved sequences in rabbit for PKG-I␣ and in human, bovine, and mouse for PKG-I␤ ( Fig. 1) .
RESULTS
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IRAG was also detected by RT-PCR in primary cultures of rabbit smooth muscle cells and after first passage using specific primers based on conserved sequences in human and bovine, including a primer based on the sequence that specifically binds PKG-I␤ (Fig. 1) . The partial amino acid sequence was 91-92% similar to human and bovine IRAG.
Both IP 3 R-I and -III but not IP 3 R-II were detected by RT-PCR in primary cultures of gastric smooth muscle cells and after first passage using primers based on conserved sequences in human, bovine, and rat (Fig. 2) . Western blot analysis of lysates derived from freshly dispersed smooth muscle cells confirmed expression of IP 3 R-I and -III but not -II (Fig. 2) . The partial amino acid sequence of IP 3 R-I was 92-94%, and that of IP 3 R-III was 90-94%, similar to those of human and rat receptors.
In vitro phosphorylation of IP 3 R-I by PKA and PKG. Exogenous PKG-I␣ holoenzyme and the catalytic subunit of PKA phosphorylated IP 3 R-I in immunoprecipi- tates obtained from lysates of dispersed smooth muscle cells (Fig. 3) . Although the extent of IP 3 R-I phosphorylation was greater with PKA than with PKG, phosphorylation by both kinases in combination was not greater than that by PKA alone (Fig. 3) . The relationship between phosphorylation by PKA and PKG was further examined by the sequential addition of the two kinases. Incubation with nonradioactive ATP in the presence of PKA for 30 min prevented further phosphorylation of IP 3 R-I by PKG. In contrast, incubation with nonradioactive ATP in the presence of PKG for 30 min did not prevent additional phosphorylation of the receptor by PKA (Fig. 4) . The extent of additional phosphorylation by PKA was similar to the difference between phosphorylation by PKA and PKG added separately (cf. Figs. 3 and 4) . The pattern implied that PKA phosphorylated the same residue(s) as PKG as well as additional PKA-specific residue(s).
In vivo phosphorylation of IP 3 R-I by PKG. Several agents that activate PKA, PKG, or both kinases were used alone and in conjunction with selective inhibitors of PKA (myristoylated PKI 14 -22 amide) or PKG [(8R,9S,11s)-(Ϫ)-9-methoxy-carbamyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,1H,-2,7b,11a-trizadizobenzo9(a,g)cycloocta(c,d,e)-trinden-1-one (KT5823)] to determine the ability of PKA and PKG to phosphorylate IP 3 R-I in vivo. Direct measurement of PKA and PKG activities in these muscle cells have shown that, at concentrations of 1 M and less, myristoylated PKI selectively inhibits PKA activity, whereas KT5823 selectively inhibits PKG activity (15, 17, 18) . The kinase activators included selective activators of PKG [8-pCPT-cGMP and sodium nitroprusside (SNP)], selective activators of PKA (cBIMPS and a low concentration of isoproterenol, Ͻ1 M), and activators of both PKA and PKG [vasoactive intestinal peptide (VIP) and high concentrations of forskolin or isoproterenol, Ͼ1 M] (8, 15, 17) . As shown previously, VIP interacts with distinct receptors to stimulate cAMP and cGMP and activate both kinases (17, 20) ; high concentrations of forskolin and isoproterenol generate high levels of cAMP that activate PKA and crossactivate PKG (8, 17) .
Two sets of parallel studies were performed: in one set, the cells were first labeled with 32 P and then treated with various agents before immunoprecipita- tion of IP 3 R-I. In a parallel set of studies, the cells were first treated with the same agents and immunoprecipitated IP 3 R-I was then treated with [␥-32 P]ATP and PKG-I␣ holoenzyme to induce complete IP 3 R-I phosphorylation. Maximum back phosphorylation (100%) occurred in untreated cells. Endogenous (i.e., in vivo) phosphorylation by PKG activators resulted in a decrease in 32 P-labeling during back phosphorylation. SNP and 8-pCPT-cGMP increased IP 3 R-I phosphorylation by 414 Ϯ 37 and 358 Ϯ 46% above basal level (basal: 510 Ϯ 46 cpm). Phosphorylation by both SNP and 8-pCPT-cGMP was virtually abolished by KT5823 but was not affected by myristoylated PKI (Fig. 5A) . Identical results were obtained using back phosphorylation to determine PKG-induced phosphorylation of IP 3 R-I (Fig. 5B) . The effect of SNP using the technique of back phosphorylation was concentration dependent (Fig. 6) .
The selective PKA activator cBIMPS had no effect on IP 3 R-I phosphorylation, whereas forskolin, which cross-activates PKG, increased IP 3 R-I phosphorylation by 342 Ϯ 43% above basal level; the increase induced by forskolin was abolished by KT5823 but was not affected by myristoylated PKI (Fig. 7A) . Similarly, 1 M isoproterenol had no effect on IP 3 R-I phosphorylation, whereas 100 M isoproterenol, which cross-activates PKG, increased IP 3 R-I phosphorylation by 320 Ϯ 38% above the basal level; the increase was virtually abolished by KT5823 but was not affected by myristoylated PKI (Fig. 8a) . VIP (1 M), which activates both PKA and PKG, increased IP 3 R-I phosphorylation by 304 Ϯ 25% above the basal level; the increase was abolished by KT5823 but was not affected by myristoylated PKI (Fig. 9A) . With each of these agents (cBIMPS, forskolin, isoproterenol, and VIP) identical results were obtained using the technique of back phosphorylation (Figs. 7B, 8B , and 9B). These results indicated that, in vivo, only PKG is capable of phosphorylating IP 3 R-I, raising the possibility that PKA, which is capable of phosphorylating the receptor in vitro, may not gain access to the receptor in vivo. This notion was examined in permeabilized smooth muscle cells. In these cells, selective activation of PKA by cBIMPS or a low concentration of isoproterenol (1 M) increased phosphorylation of IP 3 R-I by 300 Ϯ 23 and 345 Ϯ 39% above the basal level (basal: 612 Ϯ 86 cpm); phosphorylation by both agents was selectively inhibited by myristoylated PKI but was not affected by KT5823 (Fig. 10) . The addition of IP 3 for 15 s elicited rapid concentration-dependent Ca 2ϩ release (EC 50 ϭ 1 nM IP 3 ) that was inhibited to the same extent by PKA or PKG (EC 50 ϭ 1 M IP 3 with either PKG or PKA), suggesting that phosphorylation of a common site by either kinase was responsible for inhibition of Ca 2ϩ release (Fig. 11 ). An increase in phosphorylation induced by a higher concentration of the catalytic subunit of PKA (1 M) or a combination of PKA and PKG-I␣ did not elicit greater inhibition of Ca 2ϩ release (50% inhibition of release by 1 M IP 3 ), implying that the site phosphorylated by PKG-I␣ mediated inhibition of IP 3 R-I activity. Treatment of the microsomes for 15 min with a selective antibody directed against the COOH terminal of IP 3 R-I but not antibodies directed against the COOH terminals of IP3R-II or IP 3 R-III strongly inhibited IP 3 -induced Ca 2ϩ release (Fig. 12) V) appear to be restricted to IP 3 R-I, which is most abundant and has the widest central and peripheral distri- butions but is often coexpressed with IP 3 R-II and/or -III (6, 38) .
Inhibition of IP 3 -induced Ca
This study shows that both IP 3 R-I and -III are expressed in gastric smooth muscle cells and that only IP 3 R-I is susceptible to phosphorylation by PKA and PKG in vitro and exclusively by PKG in vivo. Sequential phosphorylation by PKA and PKG in vitro shows that PKA phosphorylates the same site as PKG (presumably S 1755 ) and an additional PKA-specific site (S 1589 ). Komalavilas and Lincoln (9, 10) previously reached similar conclusions in their studies of PKAand PKG-dependent phosphorylation of IP 3 R-I in cerebellar and vascular smooth muscle tissues. In the present study, phosphorylation of IP 3 R-I in microsomes by PKG or PKA inhibited IP 3 -induced Ca 2ϩ release to the same extent; combined phosphorylation by PKA and PKG did not cause further inhibition of Ca 2ϩ release, implying that inhibition was mediated by phosphorylation of the PKG-specific site (S 1755 ).
Two experimental strategies that yielded similar results were used to characterize PKA-and PKG-specific phosphorylation. In one, PKG and PKA were selectively activated in the presence or absence of specific kinase inhibitors in cells prelabeled with 32 P and IP 3 R-I was immunoprecipitated to determine the extent and specificity of phosphorylation. In the other, unlabeled cells were treated in similar fashion and immunoprecipitated IP 3 R-I was subsequently phosphorylated by PKG-I␣ holoenzyme. PKG was selectively activated by the cGMP analog 8-pCPT-cGMP and SNP, whereas PKA was selectively activated by the cAMP analog cBIMPS and low concentrations of isoproterenol (1 M). PKG and PKA were also activated concurrently by 1) VIP, which interacts with VPAC2 receptors to stimulate cAMP formation and with the natriuretic peptide clearance receptors to stimulate sequentially NO and cGMP formation (20) ; and 2) high concentrations of forskolin (10 M) or isoproterenol (100 M), which stimulates cAMP formation in amounts that activate PKA and cross-activate PKG (8, 13, 17) . These experiments showed clearly that activation of PKA alone by cBIMPS or 1 M isoproterenol did not induce IP 3 R-I phosphorylation in vivo. When PKA was activated concurrently with PKG by VIP, forskolin, or 100 M isoproterenol, IP 3 R-I phosphorylation was selectively inhibited by KT5823, implying that it was mediated by PKG. Previous studies in vascular smooth muscle also showed that IP 3 R-I phosphorylation induced by forskolin reflected crossactivation of PKG, because phosphorylation was strongly inhibited by KT5823 and was only weakly inhibited by KT5720, a preferential inhibitor of PKA (10) . When used at low concentrations (1 M and less), KT5823 and myristoylated PKI inhibit selectively PKG and PKA, respectively, as shown in previous studies by direct measurement of PKA and PKG activities in gastric smooth muscle cells (15, 17) .
In permeabilized smooth muscle cells, unlike intact cells, PKA phosphorylated IP 3 R-I, and the phosphorylation was reversed by a selective PKA inhibitor (Fig.  10) . As shown previously, IP 3 -induced Ca 2ϩ release in permeabilized gastric smooth muscle cells was inhibited by PKG and PKA, and the inhibition was reversed by selective PKG and PKA inhibitors, respectively (17) . In light of the present study, we propose that permeabilization enables PKA to gain access to and phosphorylate IP 3 R-I and thus inhibit Ca 2ϩ release. Both isoforms of PKG-I (PKG-I␣ and PKG-I␤) were identified by RT-PCR in cultured gastric smooth muscle cells. Although both PKG-I␣ and -I␤ are often coexpressed, the former appears to be the predominant isoform in the peripheral tissues of most mammalian species, including human, bovine, rabbit, and mouse (5, 7, 11, 29, 35). As noted above, PKG-I␣ is more sensitive to activation by cGMP and is susceptible to cross-activation by cAMP (12, 29 (3) . Transfection of PKG-I␣ into smooth muscle cells derived from mice deficient in both PKG-I isoforms restored the ability of PKG activators (NO donors and 8-bromo-cGMP) to inhibit agonist-induced Ca 2ϩ transients, whereas transfection of PKG-I␤ had no effect (3).
Although IRAG was expressed in gastric smooth muscle cells, the evidence suggests that PKG-I␣ rather than PKG-I␤ and IRAG was involved in IP 3 R-I phosphorylation and IP 3 -dependent Ca 2ϩ release. The results obtained with forskolin and high concentrations of isoproterenol imply that PKG-I␣ was involved in IP 3 R-I phosphorylation and IP 3 -dependent Ca 2ϩ release (17) , because this isoform is preferentially crossactivated by cAMP. Furthermore, the results of back phosphorylation with PKG-I␣ holoenzyme were identical to those obtained by activating endogenous PKG-I in vivo. In permeabilized smooth muscle cells, IP 3 R-I could be specifically phosphorylated by PKA using a selective activator of PKA (cBIMPS) or a low concentration of isoproterenol: phosphorylation of IP 3 R-I by PKA did not require IRAG, which does not bind to PKA. Phosphorylation of IP 3 R-I in microsomes by PKG-I␣ holoenzyme or the catalytic subunit of PKA inhibited Ca 2ϩ release induced by the addition of various concentrations of IP 3 , implying that phosphorylation of the receptor was the proximate cause of inhibition of Ca 2ϩ release. Forskolin and isoproterenol have been the agents of choice in evaluating the role of cAMP in mediating smooth muscle relaxation. This and other studies (8, 17) clearly show that, in intact smooth muscle cells, this cyclic nucleotide acts, at least in part, by crossactivating PKG-I to induce IP 3 R-I phosphorylation and inhibition of IP 3 -dependent Ca 2ϩ release. Lower levels of cAMP that do not cross-activate PKG probably inhibit agonist-induced Ca 2ϩ release in intact smooth muscle cells by inhibiting IP 3 formation. Our recent studies in gastric smooth muscle cells indicate that although PKA and PKG do not directly phosphorylate and inhibit PLC-␤1, they can reduce the ability of G␣q to activate PLC-␤1 (21) . Both kinases phosphorylate RGS4, which further accelerates the hydrolysis of G␣ qbound GTP (21) . Thus inhibition of agonist-induced Ca 2ϩ release is the net outcome of at least two processes: a proximal process involving inhibition of IP 3 formation that can be evoked by both PKG and PKA and a more distal process involving phosphorylation of IP 3 R-I and inhibition of IP 3 -induced Ca 2ϩ release that is PKG-specific. The precise contribution of each process has not been determined.
It is worth emphasizing that inhibition of Ca 2ϩ mobilization is relevant only to the initial transient contraction mediated by Ca 2ϩ /calmodulin-dependent activation of myosin light chain kinase and phosphorylation of MLC 20 . Sustained MLC 20 phosphorylation and contraction are largely Ca 2ϩ independent and reflect inhibition of MLC phosphatase via at least two pathways that involve activation of RhoA and its associated kinase (22, 30) . Relaxation of sustained contraction results from inhibition of RhoA activity by both PKA and PKG (22, 27) .
